Author: Donald L. Drakeman
Publisher: Oxford University Press
ISBN: 0195084004
Category : Biotechnology industries
Languages : en
Pages : 241
Book Description
"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--
From Breakthrough to Blockbuster
Author: Donald L. Drakeman
Publisher: Oxford University Press
ISBN: 0195084004
Category : Biotechnology industries
Languages : en
Pages : 241
Book Description
"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--
Publisher: Oxford University Press
ISBN: 0195084004
Category : Biotechnology industries
Languages : en
Pages : 241
Book Description
"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--
Science Business
Author: Gary P. Pisano
Publisher: Harvard Business Press
ISBN: 9781591398400
Category : Business & Economics
Languages : en
Pages : 278
Book Description
Why has the biotechnology industry failed to perform up to expectations? This book attempts to answer this question by providing a critique of the industry. It reveals the causes of biotech's problems and offers an analysis on how the industry works. It also provides prescriptions for companies, seeking ways to improve the industry's performance.
Publisher: Harvard Business Press
ISBN: 9781591398400
Category : Business & Economics
Languages : en
Pages : 278
Book Description
Why has the biotechnology industry failed to perform up to expectations? This book attempts to answer this question by providing a critique of the industry. It reveals the causes of biotech's problems and offers an analysis on how the industry works. It also provides prescriptions for companies, seeking ways to improve the industry's performance.
Commercial Biotechnology
Author:
Publisher:
ISBN:
Category : Biotechnology industries
Languages : en
Pages : 28
Book Description
Publisher:
ISBN:
Category : Biotechnology industries
Languages : en
Pages : 28
Book Description
Building Biotechnology
Author: Yali Friedman
Publisher: Thinkbiotech
ISBN: 9780973467635
Category : Business & Economics
Languages : en
Pages : 306
Book Description
Building Biotechnology helps readers start and manage biotechnology companies and understand the business of biotechnology. This acclaimed book describes the convergence of scientific, political, regulatory, and commercial factors that drive the biotechnology industry: * Cultivate a career in biotechnology, with or without an MBA or Ph.D. * Fund and assemble a company * Manage research and development, alliances, and funding * Understand the diverse factors defining the biotechnology industry * Invest intelligently in biotechnology This second edition significantly expands upon the foundation laid by the first, updating recent developments and adding significantly more case studies, informative figures and tables.
Publisher: Thinkbiotech
ISBN: 9780973467635
Category : Business & Economics
Languages : en
Pages : 306
Book Description
Building Biotechnology helps readers start and manage biotechnology companies and understand the business of biotechnology. This acclaimed book describes the convergence of scientific, political, regulatory, and commercial factors that drive the biotechnology industry: * Cultivate a career in biotechnology, with or without an MBA or Ph.D. * Fund and assemble a company * Manage research and development, alliances, and funding * Understand the diverse factors defining the biotechnology industry * Invest intelligently in biotechnology This second edition significantly expands upon the foundation laid by the first, updating recent developments and adding significantly more case studies, informative figures and tables.
Commercial Biotechnology
Author:
Publisher:
ISBN:
Category : Biological products
Languages : en
Pages : 604
Book Description
Publisher:
ISBN:
Category : Biological products
Languages : en
Pages : 604
Book Description
Welcome to BioTech Nation
Author: Moira Anne Gunn
Publisher: Amacom Books
ISBN: 9780814409237
Category : Biography & Autobiography
Languages : en
Pages : 286
Book Description
Funny, entertaining, and informative, the host of public radios "Tech Nation" gives readers a unique, inside look at biotechnology today and a glimpse at what could be in store for tomorrow.
Publisher: Amacom Books
ISBN: 9780814409237
Category : Biography & Autobiography
Languages : en
Pages : 286
Book Description
Funny, entertaining, and informative, the host of public radios "Tech Nation" gives readers a unique, inside look at biotechnology today and a glimpse at what could be in store for tomorrow.
Biotechnology Entrepreneurship Bootcamp
Author: Stephen M. Sammut
Publisher: Thinkbiotech LLC
ISBN: 9781934899359
Category :
Languages : en
Pages : 104
Book Description
This issue of the Journal of Commercial Biotechnology focuses on the proceedings of the Seventh Annual Biotechnology Entrepreneurship Boot Camp held. Topics covered include Product or Company; Reimbursement; Regulation; Building the Management Team; The Plan and the Pitch; Working With the Media; Partnering; and Capitalization.
Publisher: Thinkbiotech LLC
ISBN: 9781934899359
Category :
Languages : en
Pages : 104
Book Description
This issue of the Journal of Commercial Biotechnology focuses on the proceedings of the Seventh Annual Biotechnology Entrepreneurship Boot Camp held. Topics covered include Product or Company; Reimbursement; Regulation; Building the Management Team; The Plan and the Pitch; Working With the Media; Partnering; and Capitalization.
Industrialization of Biology
Author: National Research Council
Publisher: National Academies Press
ISBN: 0309316553
Category : Science
Languages : en
Pages : 158
Book Description
The tremendous progress in biology over the last half century - from Watson and Crick's elucidation of the structure of DNA to today's astonishing, rapid progress in the field of synthetic biology - has positioned us for significant innovation in chemical production. New bio-based chemicals, improved public health through improved drugs and diagnostics, and biofuels that reduce our dependency on oil are all results of research and innovation in the biological sciences. In the past decade, we have witnessed major advances made possible by biotechnology in areas such as rapid, low-cost DNA sequencing, metabolic engineering, and high-throughput screening. The manufacturing of chemicals using biological synthesis and engineering could expand even faster. A proactive strategy - implemented through the development of a technical roadmap similar to those that enabled sustained growth in the semiconductor industry and our explorations of space - is needed if we are to realize the widespread benefits of accelerating the industrialization of biology. Industrialization of Biology presents such a roadmap to achieve key technical milestones for chemical manufacturing through biological routes. This report examines the technical, economic, and societal factors that limit the adoption of bioprocessing in the chemical industry today and which, if surmounted, would markedly accelerate the advanced manufacturing of chemicals via industrial biotechnology. Working at the interface of synthetic chemistry, metabolic engineering, molecular biology, and synthetic biology, Industrialization of Biology identifies key technical goals for next-generation chemical manufacturing, then identifies the gaps in knowledge, tools, techniques, and systems required to meet those goals, and targets and timelines for achieving them. This report also considers the skills necessary to accomplish the roadmap goals, and what training opportunities are required to produce the cadre of skilled scientists and engineers needed.
Publisher: National Academies Press
ISBN: 0309316553
Category : Science
Languages : en
Pages : 158
Book Description
The tremendous progress in biology over the last half century - from Watson and Crick's elucidation of the structure of DNA to today's astonishing, rapid progress in the field of synthetic biology - has positioned us for significant innovation in chemical production. New bio-based chemicals, improved public health through improved drugs and diagnostics, and biofuels that reduce our dependency on oil are all results of research and innovation in the biological sciences. In the past decade, we have witnessed major advances made possible by biotechnology in areas such as rapid, low-cost DNA sequencing, metabolic engineering, and high-throughput screening. The manufacturing of chemicals using biological synthesis and engineering could expand even faster. A proactive strategy - implemented through the development of a technical roadmap similar to those that enabled sustained growth in the semiconductor industry and our explorations of space - is needed if we are to realize the widespread benefits of accelerating the industrialization of biology. Industrialization of Biology presents such a roadmap to achieve key technical milestones for chemical manufacturing through biological routes. This report examines the technical, economic, and societal factors that limit the adoption of bioprocessing in the chemical industry today and which, if surmounted, would markedly accelerate the advanced manufacturing of chemicals via industrial biotechnology. Working at the interface of synthetic chemistry, metabolic engineering, molecular biology, and synthetic biology, Industrialization of Biology identifies key technical goals for next-generation chemical manufacturing, then identifies the gaps in knowledge, tools, techniques, and systems required to meet those goals, and targets and timelines for achieving them. This report also considers the skills necessary to accomplish the roadmap goals, and what training opportunities are required to produce the cadre of skilled scientists and engineers needed.
Science Lessons
Author: Gordon M. Binder
Publisher: Harvard Business Review Press
ISBN:
Category : Biography & Autobiography
Languages : en
Pages : 326
Book Description
Under Gordon Binder's leadership, Amgen became the world's largest and most successful biotech company in the world. This text describes what it really takes to manage risk, financing, creative employees, and intellectual property on the international stage.
Publisher: Harvard Business Review Press
ISBN:
Category : Biography & Autobiography
Languages : en
Pages : 326
Book Description
Under Gordon Binder's leadership, Amgen became the world's largest and most successful biotech company in the world. This text describes what it really takes to manage risk, financing, creative employees, and intellectual property on the international stage.
Commercial biotechnology : an international analysis.
Author:
Publisher: DIANE Publishing
ISBN: 1428923632
Category :
Languages : en
Pages : 603
Book Description
Publisher: DIANE Publishing
ISBN: 1428923632
Category :
Languages : en
Pages : 603
Book Description